ZNF521 and neoplasm: The results of TCGA database showed that the expression of ZNF521 was decreased in 178 primary tumours compared with 4 normal tissue samples (Figure 8C), and its promoter methylation levels were increased in 184 primary tumours compared with 10 normal tissue samples (Figure 8D), which supported the results of our cohort study that ZNF521 was under‐expressed in 39 tumour samples from 12 patients.